Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02039947
Title Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Novartis Investigative Site Birmingham Alabama 35243 United States Details
Novartis Investigative Site San Francisco California 94115 United States Details
Novartis Investigative Site Aurora Colorado 80045 United States Details
Novartis Investigative Site Atlanta Georgia 30322 United States Details
Novartis Investigative Site Atlanta Georgia 30341 United States Details
Novartis Investigative Site Boston Massachusetts 02215 United States Details
Novartis Investigative Site Chapel Hill North Carolina 27599 United States Details
Novartis Investigative Site Columbus Ohio 43210 United States Details
Novartis Investigative Site Pittsburgh Pennsylvania 15232 United States Details
Novartis Investigative Site Nashville Tennessee 37232 United States Details
Novartis Investigative Site Houston Texas 77030 United States Details
Novartis Investigative Site North Sydney New South Wales 2060 Australia Details
Novartis Investigative Site Greenslopes Queensland 4120 Australia Details
Novartis Investigative Site Melbourne Victoria 3004 Australia Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Hamilton Ontario L8V 5C2 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Montreal Quebec H2W 1S6 Canada Details
Novartis Investigative Site Boulogne-Billancourt 92100 France Details
Novartis Investigative Site Lille 59037 France Details
Novartis Investigative Site Marseille Cedex 5 13385 France Details
Novartis Investigative Site Montpellier cedex 5 34295 France Details
Novartis Investigative Site Nantes Cedex 1 44093 France Details
Novartis Investigative Site Paris Cedex 10 75475 France Details
Novartis Investigative Site Pierre-Benite cedex 69495 France Details
Novartis Investigative Site Poitiers 86021 France Details
Novartis Investigative Site Rennes Cedex 35042 France Details
Novartis Investigative Site Toulouse cedex 31052 France Details
Novartis Investigative Site Villejuif cedex 94805 France Details
Novartis Investigative Site Heidelberg Baden-Wuerttemberg 69120 Germany Details
Novartis Investigative Site Tuebingen Baden-Wuerttemberg 72076 Germany Details
Novartis Investigative Site Muenchen Bayern 80337 Germany Details
Novartis Investigative Site Hannover Niedersachsen 30449 Germany Details
Novartis Investigative Site Koeln Nordrhein-Westfalen 50937 Germany Details
Novartis Investigative Site Kiel Schleswig-Holstein 24105 Germany Details
Novartis Investigative Site Gera Thueringen 07548 Germany Details
Novartis Investigative Site Milano Lombardia 20133 Italy Details
Novartis Investigative Site Milano Lombardia 20141 Italy Details
Novartis Investigative Site Padova Veneto 35128 Italy Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Las Palmas De Gran Canaria 35016 Spain Details
Novartis Investigative Site Madrid 28007 Spain Details
Novartis Investigative Site Malaga 29010 Spain Details
Novartis Investigative Site Palma de Mallorca 07198 Spain Details
Novartis Investigative Site Pamplona 31008 Spain Details
Novartis Investigative Site Valencia 46009 Spain Details
Novartis Investigative Site Zaragoza 50009 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field